SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Want to cut your energy bills? Here’s how five experts are doing it 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
NOVATO, Calif., March 02, 2017 -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, will present at the following investor conferences:
- Shalini Sharp, the company’s Chief Financial Officer, will present at the Cowen and Company 37th Annual Health Care Conference on Tuesday, March 7, 2017 at 8:00 am ET in Boston, MA.
- Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer, will present at the Barclays Global Healthcare Conference on Wednesday, March 15, 2017 at 11:15 am ET in Miami, FL.
The live and archived webcasts of the company presentations will be accessible from the company’s website at http://ir.ultragenyx.com/events.cfm. The replays will be available for 90 days.
About Ultragenyx
Ultragenyx is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company’s website at www.ultragenyx.com.
Contact Ultragenyx Pharmaceutical Inc. Investors & Media Ryan Martins 844-758-7273
